American Association for Cancer Research
15357163mct170081-sup-177777_2_supp_4140562_ysm5y0.png (1.58 MB)

Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer

Download (1.58 MB)
posted on 2023-04-03, 15:42 authored by Elisa Zanini, Louay S. Louis, Jane Antony, Evdoxia Karali, Imoh S. Okon, Arthur B. McKie, Sebastian Vaughan, Mona El-Bahrawy, Justin Stebbing, Chiara Recchi, Hani Gabra

SKOV3, OV90 and SKBR3 cells were virally transduced to express OPCML


Ovarian Cancer Action Research Centre Core Funding



Opioid-binding protein/cell adhesion molecule-like (OPCML) is a tumor-suppressor gene that is frequently inactivated in ovarian cancer and many other cancers by somatic methylation. We have previously shown that OPCML exerts its suppressor function by negatively regulating a spectrum of receptor tyrosine kinases (RTK), such as ErbB2/HER2, FGFR1, and EphA2, thus attenuating their related downstream signaling. The physical interaction of OPCML with this defined group of RTKs is a prerequisite for their downregulation. Overexpression/gene amplification of EGFR and HER2 is a frequent event in multiple cancers, including ovarian and breast cancers. Molecular therapeutics against EGFR/HER2 or EGFR only, such as lapatinib and erlotinib, respectively, were developed to target these receptors, but resistance often occurs in relapsing cancers. Here we show that, though OPCML interacts only with HER2 and not with EGFR, the interaction of OPCML with HER2 disrupts the formation of the HER2-EGFR heterodimer, and this translates into a better response to both lapatinib and erlotinib in HER2-expressing ovarian and breast cancer cell lines. Also, we show that high OPCML expression is associated with better response to lapatinib therapy in breast cancer patients and better survival in HER2-overexpressing ovarian cancer patients, suggesting that OPCML co-therapy could be a valuable sensitizing approach to RTK inhibitors. Mol Cancer Ther; 16(10); 2246–56. ©2017 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager